Money Runners

[TPX]

$PMCB PharmaCyte Biotech’s Cannabinoid Therapy

JANUARY 2, 2017

KEY TOPICS

In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes.

POSSIBLY USEFUL

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box .”

KEY TOPICS

In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. Pharmacyte Biotech Inc (OTCMKTS:PMCB) has presented its pre-Investigational New Drug conference bundle to the U.S. FDA for its therapy in LAPC that is inoperable.

In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. PharmaCyte Biotech is developing treatments for cancer based upon chemical constituents of the Cannabis plant, known as cannabinoids.

PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form.

Prodrugs of THC and CBD are candidates for this program, and brain cancer is PharmaCyte?s initial target using this cannabinoid therapy. PharmaCyte?s cannabinoid program at the University of Northern Colorado involves developing a bioengineered cell line that will activate a cannabinoid-based prodrug into its cancer-killing form and then encapsulating these cells using the Cell-in-a-Box encapsulation technology.

When the capsules are implanted near the tumor and the cannabinoid prodrug is administered to a patient, targeted chemotherapy results.

We will continue to administer ifosfamide until the patients receive no further benefit from our therapy. The package allows the FDA to know a full history of firm?s therapy, comprising info on the previous clinical trials and preclinical studies that were performed applying the Cell-in-a-Box technology together with low doses of drug ifosfamide. This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.PharmaCyte?s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. This refers particularly to those patients who received first line therapy, e.g. a very strong one (FOLFIRINOX) or combination of gemcitabine with Abraxane. Pharmacyte?s CEO Kenneth L. Waggoner reported that the pre-IND package application marks a notable initiative that they have completed in its plans to get pancreatic cancer therapy. AFTER this therapy, there is nothing left, especially an alternative with a low likelihood of side effects.

POSSIBLY USEFUL

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box .” PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.

LAGUNA HILLS, Calif., Dec. 07, 2016 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology.

PharmaCyte Biotech is also working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. Pharmacyte Biotech is also working on a regimen for insulin-dependent Type 2 diabetes and Type 1 diabetes.

This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year. PharmaCyte?s Chief Executive Officer, Kenneth L. Waggoner, commented, “It is clear that PharmaCyte is on the right track to developing targeted therapies for deadly cancers. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body.

They include PharmaCyte’s ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte?s intellectual property and PharmaCyte?s continued ability to raise capital.

http://providencehightech.com/pharmacyte-biotechs-cannabinoid-therapy/